edaravone has been researched along with Parkinson Disease in 4 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The major hallmark of Parkinson's disease (PD) is the degeneration of dopaminergic neurons in the substantia nigra (SN), which is responsible for the core motor symptoms of PD." | 1.72 | The Effects of Novel Formulations of Edaravone and Curcumin in the Mouse Intrastriatal Lipopolysaccharide Model of Parkinson's Disease. ( Bobrovskaya, L; Deng, I; Garg, S; Zhou, XF, 2022) |
| " Edaravone might be a hopeful therapeutic option for PD, although the high therapeutic dosage remains to be solved for the clinical application." | 1.35 | Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. ( Agari, T; Baba, T; Date, I; Jing, M; Kameda, M; Leung, H; Matsui, T; Miyoshi, Y; Morimoto, T; Muraoka, K; Shingo, T; Tajiri, N; Uozumi, T; Wang, F; Yasuhara, T; Yuan, WJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, I | 1 |
| Garg, S | 1 |
| Zhou, XF | 1 |
| Bobrovskaya, L | 1 |
| Jiao, Y | 1 |
| Zheng, Y | 1 |
| Song, CJ | 1 |
| Kapoor, S | 1 |
| Yuan, WJ | 1 |
| Yasuhara, T | 1 |
| Shingo, T | 1 |
| Muraoka, K | 1 |
| Agari, T | 1 |
| Kameda, M | 1 |
| Uozumi, T | 1 |
| Tajiri, N | 1 |
| Morimoto, T | 1 |
| Jing, M | 1 |
| Baba, T | 1 |
| Wang, F | 1 |
| Leung, H | 1 |
| Matsui, T | 1 |
| Miyoshi, Y | 1 |
| Date, I | 1 |
4 other studies available for edaravone and Parkinson Disease
| Article | Year |
|---|---|
The Effects of Novel Formulations of Edaravone and Curcumin in the Mouse Intrastriatal Lipopolysaccharide Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Anti-Inflammatory Agents; Curcumin; Disease Models, Animal; Edaravone; Lip | 2022 |
[Protective effect of edaravone on balance of mitochondrial fusion and fission in MPP
Topics: 1-Methyl-4-phenylpyridinium; Animals; Dynamins; Edaravone; GTP Phosphohydrolases; Mitochondria; Mito | 2020 |
Edaravone and Its Protective Effects against Disease Progression in Neurological Conditions Besides Strokes.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Edaravone; Humans; | 2017 |
Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.
Topics: Animals; Antipyrine; Cell Survival; Cells, Cultured; Dopamine; Edaravone; Female; Mice; Mice, Inbred | 2008 |